
CANCER HAS
NO BORDERS.
NEITHER
DO WE®
BeiGene

The BeiGene Story

A global biopharmaceutical innovator focused on improving treatment outcomes and patient access

BeiGene is a fully-integrated biopharmaceutical company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China's National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception.

BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on developing novel cancer therapies where there is global unmet need.

Our broad product portfolio and pipeline include:

- 3 wholly owned late-stage oncology candidates, including one approved in the U.S. and one approved in China
- 27 Phase 3 or potentially registration-enabling trials ongoing, 60+ studies in total
- 32 clinical or commercial stage assets including seven internally developed and 25 in-licensed

BeiGene has built a strong innovative pipeline of clinical drug candidates through internal discovery and collaborations.

Transformative Collaboration with Amgen

This global strategic oncology collaboration expands access to important oncology medicines for patients in China and around the globe with:

- BeiGene commercializing three Amgen oncology products in China — XGEVA® (denosumab), KYPROLIS™ (carfilzomib), and BLINCYTO® (blinatumomab)
- Companies jointly developing 20 Amgen oncology pipeline assets globally, with BeiGene leading development in China
- Amgen investing $2.8B for a 20.5% stake in BeiGene

3,400+
employees
(as of January 29, 2020)

10 offices
on 4 continents

Trials in 35
countries and regions



BEIGENE'S COMMERCIAL PRODUCT PORTFOLIO

BRUKINSA™ (zanubrutinib)	• U.S. FDA accelerated approval in November 2019 for relapsed/ refractory (R/R) mantle cell lymphoma
Tislelizumab	• China NMPA approval in R/R classical Hodgkin's lymphoma
XGEVA® (denosumab)	• China NMPA approval in giant cell tumor of bone • In-licensed from Amgen, rights in China

BEIGENE'S SELECTED INVESTIGATIONAL PIPELINE[1]

Zanubrutinib	• Potent second generation small molecule inhibitor of Bruton's tyrosine kinase • Currently being investigated as a monotherapy and in combination with other therapies in multiple hematologic malignancies
Tislelizumab	• Humanized IgG4 anti-PD-1 monoclonal antibody • Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies
Pamiparib	• Investigational small molecule inhibitor of PARP1 and PARP2 • Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors
Lifirafenib	• Investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities • Currently being investigated as a monotherapy and in combination with mirdametinib (MEK inhibitor from SpringWorks Therapeutics) in solid tumors
BGB-A333	• Investigational humanized monoclonal antibody against the immune checkpoint receptor ligand PD-L1 • Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors

[1]*Abbreviated pipeline as of January 9, 2020. For full pipeline, visit beigene.com/science-and-product-portfolio/pipeline*

REVLIMID® (lenalidomide)	• China NMPA approvals in R/R multiple myeloma and multiple myeloma • In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
ABRAXANE® (albumin-bound paclitaxel)	• China NMPA approval in breast cancer • In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
VIDAZA® (azacitidine)	• China NMPA approvals in myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia • In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China

BGB-A425	• Investigational humanized IgG1-variant monoclonal antibody against TIM-3 • Currently being investigated in combination with tislelizumab in solid tumors
BGB-A1217	• Investigational TIGIT monoclonal antibody • Currently being investigated as in combination with tislelizumab in solid tumors
BGB-11417	• Investigational small molecule Bcl-2 inhibitor • Currently being investigated as a monotherapy and in combination with zanubrutinib in hematologic malignancies
Sitravatinib	• Investigational spectrum-selective kinase inhibitor of receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER) and split family receptors (VEGFR2, KIT) • Currently being investigated in combination with tislelizumab in solid tumors • In-licensed from Mirati Therapeutics, rights in Asia ex-Japan, AU, NZ
ZW25	• Investigational HER2-targeted bispecific antibody • Currently being investigated in combination with tislelizumab in solid tumors • In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ
ZW49	• Investigational HER2-targeted bispecific antibody drug conjugate (ADC) • In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ
AMG 510	• Investigational $KRAS^{G12C}$ small molecule inhibitor • In-licensed from Amgen, rights in China



Meet Members of Our Leadership Team

BeiGene employees are dedicated to translating groundbreaking science into quality innovative cancer therapies.

With a global headcount of over 3,400 employees, more than 1,000 are devoted to global clinical development and approximately 1,000 are in commercial operation.

John V. Oyler
Chairman, Founder & CEO
BioDuro, Galenea, Telephia, Genta, McKinsey & Company

Xiaodong Wang, Ph.D.
Founder & Chairman SAB
NIBS: National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences

Xiaobin Wu, Ph.D.
GM of China & President
Pfizer, Wyeth, Bayer

Jane Huang, M.D.
CMO, Hematology
Acerta, Genentech

Yong (Ben) Ben, M.D.
CMO, Immuno-Oncology
BioAtla, AstraZeneca

Eric Hedrick, M.D.
Chief Advisor
Genentech, Pharmacyclics, Epizyme

Josh Neiman
Head of U.S. Commercial
Flatiron Health, Onyx Pharmaceuticals, Genentech

Guillaume Vignon, Ph.D.
SVP, Business Development
Merck KGaA

Lai Wang, Ph.D.
SVP, Head of Global Research, Clinical Operation, Biometrics & APAC Clinical Development
Joyant Pharmaceuticals, Howard Hughes Medical Institute

Todd Yancey, M.D.
SVP, Global Medical Affairs & New Market Development
BioMarin, Clovis Oncology, Medivation, Onyx Pharmaceuticals

Our Commitment

BeiGene's commitment is to never compromise on the safety, compliance, or quality of our products, our research, or our services. We are focused on serving patients by delivering quality drug products that consistently meet or exceed all customer and regulatory requirements. Each BeiGene employee and partner is responsible for achieving our objectives and for looking at any opportunity where we can improve upon our high standards of performance.

BeiGene conducts its clinical trials in accordance with the regulatory requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the China National Medical Products Administration (NMPA), as applicable. Likewise, BeiGene's own state-of-the-art manufacturing facilities, located in China, are fully compliant with Good Manufacturing Practice (GMP) requirements of the U.S., European and Chinese authorities and subject to inspection and approval by these authorities. It has also contracted with leading American and German manufacturers for production of its drug candidates.

Our employees look forward to connecting with you to provide additional insight into BeiGene.

Contact us at:
888-123-4455 or info@beigene.com

www.beigene.com

@BeiGeneUSA

BeiGene